Лекарственно-индуцированная (медикаментозная) депрессия в неврологической практике

 Одной из причин развития депрессии является прием некоторых лекарственных средств (ЛС), в таком случае используют термины «лекарственно-индуцированная депрессия» (ЛИД), «медикаментозная депрессия» или «ятрогенная депрессия». Симптомы ЛИД сходны с теми, которые наблюдаются у пациентов с другими типами депрессии. ЛИД  взаимосвязана с повышением заболеваемости и смертности. Ее  развитие приводит к снижению приверженности лечению, а в ряде  случаев – к прекращению приема препаратов, имеющих жизненно  важное значение. Главное в ведении пациентов с ЛИД – быстрое  выявление и коррекция симптомов, а также принятие своевременных мер, предупреждающих их развитие, при назначении определенных ЛС.  Обсуждаются особенности течения ЛИД, патогенетические  механизмы и факторы риска ее развития, возможные подходы к  терапии и профилактике. 

1. Оганов РГ, Ольбинская ЛИ, Смулевич АБ и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;(1):48-55.

2. Парфенов ВА. Депрессия в неврологической практике и терапия Паксилом. Атмосфера. Неврология. 2004;(1):43-4.

3. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.

4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

5. Сычев ДА, Жучков АВ, Терещенко ОВ, Иващенко ДВ. Постепенная отмена (депрескрайбинг) бензодиазепиновых транквилизаторов. Неврология, нейропсихиатрия, психосоматика. 2019;11(1):89-95. doi: 10.14412/2074-2711-2019-1-89-95

6. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008 Mar 2;299(10):1121-2. doi: 10.1001/jama.299.10.1121

7. Warnock JK, Bundren JC. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull. 1997;33(2):311-6.

8. Warnock JK, Bundren JC, Morris DW. Depressive mood symptoms associated with ovarian suppression. Fertil Steril. 2000 Nov;74(5):984-6. doi: 10.1016/s0015-0282(00)01607-1

9. Toren P, Dor J, Mester R, et al. Depression in women treated with a gonadotropin-releasing hormone agonist. Biol Psychol. 1996 Mar 1;39(5):378-82. doi: 10.1016/0006-3223(95)00473-4

10. Steingold KA, Cedars M, Lu JK, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol. 1987 Mar;69(3 Pt 1):403-11.

11. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992 Jan 4;339(8784):1-15.

12. Grigg JR. Prednisone mood disorder with associated catatatonia. Geriatr Psychiatry Neurol. Jan-Mar 1989;2(1):41-4. doi: 10.1177/089198878900200108

13. Available from: https://www.drugs.com (accessed:19.05.2020).

14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047

15. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001 Oct;45(4):515-9. doi: 10.1067/mjd.2001.117730

16. O'Donnell J. Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. Am J Ther. Mar-Apr 2003;10(2):148-59. doi: 10.1097/00045391-200303000-00012

17. Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy. Biol Psychiatry. 1998 Mar 15;43(6):464-5. doi: 10.1016/s0006-3223(97)00396-x

18. Тювина НА. Дифференциальная диагностика и лечение депрессивных расстройств у женщин в период климактерия. Неврология, нейропсихиатрия, психосоматика. 2011;3(1):66-71. doi: 10.14412/2074-2711-2011-137

19. Тювина НА, Воронина ЕО, Балабанова ВВ, Гончарова ЕМ. Взаимосвязь и взаимовлияние менструально-генеративной функции и депрессивных расстройств у женщин. Неврология, нейропсихиатрия, психосоматика. 2018;10(2):45-51. doi: 10.14412/2074-2711-2018-2-45-51

20. Patten SB, Williams JV, Love EJ. Self-reported depressive symptoms in association with medication exposures among medical

21. inpatients: a cross-sectional study. Can J Psychiatry. 1995 Jun;40(5):264-9.

22. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005 Dec 1;41(11):1648-53. doi: 10.1086/497835. Epub 2005 Oct 19.

23. Alzoubi KH, Khabour OF, Hassan RE, et al. The effect of genetic polymorphisms of RARA gene on the adverse effects profile of isotretinoin-treated acne patients. Int J Clin Pharmacol Ther. 2013 Aug;51(8):631-40. doi: 10.5414/CP201874

24. Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia. 2003 Dec;44(12):1573-7. doi: 10.1111/j.0013-9580.2003.19103.x

25. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003 May;44(5):659-63. doi: 10.1046/j.1528-1157.2003.05402.x

26. Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia. 2009 May;50(5):1072-6. doi: 10.1111/j.1528-1167.2008.01799.x. Epub 2008 Oct 24.

27. Galvao-de Almeida A, Quarantini LC, Tartaglioni AG, et al. Serotonin-1A receptor CC genotype is associated with persistent depression related to interferon-alpha in hepatitis C patients. Gen Hosp Psychiatry. May-Jun 2014;36(3):255-60. doi: 10.1016/j.genhosppsych.2013.12.007. Epub 2013 Dec 24.

28. Cozzolongo R, Porcelli P, Cariola F, et al. Serotonin gene polymorphisms and lifetime mood disorders in predicting interferoninduced depression in chronic hepatitis C. J Affect Disord. 2015 Sep 1;183:90-7. doi: 10.1016/j.jad.2015.04.056. Epub 2015 May 9.

29. Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008 Apr;57(4):531-6. doi: 10.1136/gut.2007.131607. Epub 2007 Dec 13.

30. Cunha ECM, Behrensdorf MF, Bavaresco V, et al. Genotype 1 of hepatitis C virus increases the risk of major despession: a 12 week prospective study. Gen Hosp Psychiatry. Jul-Aug 2015;37(4):283-7. doi: 10.1016/j.genhosppsych.2015.03.016. Epub 2015 Mar 31.

31. Whale R, Fialho R, Rolt M, et al. Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. J Psychosom Res. 2015 Dec;79(6):640-5. doi: 10.1016/j.jpsychores.2015.06.003. Epub 2015 Jun 18.

32. Hamad T. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. Available from: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065bl-10-TAB08-Hammads-Review.pdf (accessed 2020 May 19).

33. Yudofsky SC. β-Blockers and Depression: The Clinician's Dilemma. JAMA. 1992 Apr 1;267(13):1826-7. doi: 10.1001/jama.1992.03480130142042

34. Pedrol E, Llibre JM, Tasias M, et al. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med. 2015 Nov;16(10):628-34. doi: 10.1111/hiv.12298. Epub 2015 Aug 4.

35. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000 Jun;31(6):1207- 11. doi: 10.1053/jhep.2000.7880

36. Victoroff JI, Benson F, Engel J, et al. Interictal depression in patients with medically intractable complex partial seizures: electroencephalography and cerebral metabolic correlates. Ann Neurol. 1990;28:221.

37. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002 Mar;63(3):194-8. doi: 10.4088/jcp.v63n0304

38. Hauser P, Khosla J, Aurora H, et al A prospective study of the incidence and openlabel treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-7. doi: 10.1038/sj.mp.4001119

39. Chen WC, Lai HC, Su WP, et al. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study. Psychiatry Investig. 2015 Jan;12(1):142-5. doi: 10.4306/pi.2015.12.1.142. Epub 2015 Jan 12.

40. Camacho A, Ng B. Methylphenidate for alpha-interferon induced depression. J Psychopharmacol. 2006 Sep;20(5):687-9. doi: 10.1177/0269881106063134. Epub 2006 Mar 13.

41. Malek-Ahmadi P, Prabhu F. Venlafaxine for treatment of interferon alfa-induced depression. Ann Pharmacother. 2006 Nov;40(11):2075. doi: 10.1345/aph.1H133. Epub 2006 Oct 17.

42. Patten SB. Psychopharmacology for the clinician psychopharmacologie pratique. J Psychiatry Neurosci. 2001 Jan;26(1):66.

43. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989 Jul;50(7):256-61.

44. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia. 1999;40 Suppl 10:S21- 47. doi: 10.1111/j.1528-1157.1999.tb00884.x

45. Sabet-Sharghi F, Hutzler JC. Prophylaxis of steroid-induced psychiatric syndromes. Psychosomatics. Winter 1990;31(1):113-4. doi: 10.1016/S0033-3182(90)72233-5

46. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001 Mar 29;344(13):961-6. doi: 10.1056/NEJM200103293441303

47. Ehret M, Sobieraj DM. Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review a nd meta-analysis. Int J Clin Pract. 2014 Feb;68(2):255-61. doi: 10.1111/ijcp.12268. Epub 2013 Dec 22.

48. Hou XJ, Xu JH, Wang J, Yu YY. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One. 2013 Oct 30;8(10):e76799.

49. doi: 10.1371/journal.pone.0076799. eCollection 2013.

50. Udina M, Hidalgo D, Navines R, et al. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014 Oct;75(10):e1113-21. doi: 10.4088/JCP.13r08800